Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

BACKGROUND: Young children living with HIV have few treatment options. We aimed to assess the efficacy and safety of dolutegravir-based antiretroviral therapy (ART) in children weighing between 3 kg and less than 14 kg. METHODS: ODYSSEY is an open-label, randomised, non-inferiority trial (10% margin...

Descripción completa

Detalles Bibliográficos
Autores principales: Amuge, Pauline, Lugemwa, Abbas, Wynne, Ben, Mujuru, Hilda A, Violari, Avy, Kityo, Cissy M, Archary, Moherndran, Variava, Ebrahim, White, Ellen, Turner, Rebecca M, Shakeshaft, Clare, Ali, Shabinah, Nathoo, Kusum J, Atwine, Lorna, Liberty, Afaaf, Bbuye, Dickson, Kaudha, Elizabeth, Mngqibisa, Rosie, Mosala, Modehei, Mumbiro, Vivian, Nanduudu, Annet, Ankunda, Rogers, Maseko, Lindiwe, Kekitiinwa, Adeodata R, Giaquinto, Carlo, Rojo, Pablo, Gibb, Diana M, Turkova, Anna, Ford, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646993/
https://www.ncbi.nlm.nih.gov/pubmed/36055295
http://dx.doi.org/10.1016/S2352-3018(22)00163-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646993/
https://www.ncbi.nlm.nih.gov/pubmed/36055295
http://dx.doi.org/10.1016/S2352-3018(22)00163-1

Ejemplares similares